Alexion Pharmaceuticals (ALXN) : Eqis Capital Management reduced its stake in Alexion Pharmaceuticals by 2.97% during the most recent quarter end. The investment management company now holds a total of 9,438 shares of Alexion Pharmaceuticals which is valued at $1,184,563 after selling 289 shares in Alexion Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Oct 4, 2016.Alexion Pharmaceuticals makes up approximately 0.07% of Eqis Capital Management’s portfolio.
Other Hedge Funds, Including , Washington Trust Bank boosted its stake in ALXN in the latest quarter, The investment management firm added 36 additional shares and now holds a total of 52 shares of Alexion Pharmaceuticals which is valued at $6,527.
Alexion Pharmaceuticals opened for trading at $122.41 and hit $123.91 on the upside on Tuesday, eventually ending the session at $123.41, with a gain of 1.04% or 1.27 points. The heightened volatility saw the trading volume jump to 12,77,144 shares. Company has a market cap of $27,674 M.
On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $1.17. The company had revenue of $753.10 million for the quarter, compared to analysts expectations of $743.05 million. The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Company shares were Reiterated by FBR & Co. on Sep 16, 2016 to “Underperform”, Firm has raised the Price Target to $ 92 from a previous price target of $82 .FBR & Co. Initiated Alexion Pharmaceuticals on Sep 15, 2016 to “Underperform”, Price Target of the shares are set at $82.Shares were Reiterated by Stifel on Jul 29, 2016 to “Buy” and Lowered the Price Target to $ 182 from a previous price target of $195 .
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.